TMCnet News
Development of Targeted and Combination Therapies to Cure Cancer Will Drive the Global Cancer Immunotherapies Market Through 2020, Says TechnavioTechnavio's latest report on the global cancer immunotherapies market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline. The top four emerging trends driving the global cancer immunotherapies market according to Technavio healthcare research analysts are:
Increase in cancer awareness Organizations such as the American Social Health Association (ASHA) and National Cervical Cancer Coalition (NCCC) have undertaken initiatives to create awareness about the prevention and control of HPV and cervical cancer. The Centers for Disease Control and Prevention provides guidelines and conducts awareness programs to screen and vaccinate underserved individuals with cervical cancer. In 2009, the International Federation of Gynecology and Obstetrics (FIGO) issued guidance to prevent cervical cancer. In 2006, the WHO's Department of Reproductive Health and Research and the Department of Chronic Diseases and Health Promotion implemented the Comprehensive Cervical Cancer Control initiative to reduce the burden of the disease. "Every year, October 25 is celebrated as the World Myelodysplastic Syndrome Awareness Day, with organizations creating awareness about the disease. Several other initiatives have been undertaken to disseminate information about the disease: The National Cancer Institute and the Leukemia and Lymphoma Society in the US, along with the Leukemia Foundation in Australia, help spread information about the disease and the associated treatment options," says Barath Palada, a lead analyst at Technavio for oncology. Emergence of targeted and combination therapies Targeted and combination therapies are being increasingly developed to treat cancer. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cuse fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2. In such circumstances, drugs such as Herceptin and Kadcyla, which target HER2 receptors, are administered as monotherapies or in combination. Targeting multiple pathways reduces the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating cancer. For example, Folfirinox is a combination of folinic acid, fluorouracil, oxaliplatin, and irinotecan, which reduces the toxic effects of other anti-cancer drugs. Fluorouracil is a fluoropyrimidine analog of the nucleoside pyrimidine. In vivo, fluorouracil is metabolized into metabolites that interfere with the normal functioning of nucleic acids. Oxaliplatin, a platinum-based compound, interferes with the DNA replication and transcription. Irinotecan, a semisynthetic derivative of camptothecin, inhibits DNA replication and triggers apoptosis. Emergence of biosimilars Unlike generic drugs, which have active pharmaceutical ingredients that are identical to original drugs, biosimilars are almost similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. They are less expensive than biologics, making them more accessible to patients. MabThera, Avastin, Herceptin, Erbitux, and Vectibix are some of the major biologics available for cancer. However, patent expiries will result in the emergence of their biosimilars. The sales of these biologics are expected to decline during the forecast period, owing to the increased sales of their biosimilar versions. Strategic alliances The global cancer immunotherapies market presents immense growth opportunities for vendors. Strategic alliances formed, in terms of collaboration and licensing, help to co-develop and commercialize drugs in different regions. Co-development agreements enable the use of technical expertise from both companies, and allow the use of regulatory and development experience gained by one company to support the pipeline candidates of the other. Such agreements ensure the in-flow of adequate funds for both the companies and reduce liability costs for individual companies in case of failures, thereby attracting more venture investments. "Seattle Genetics collaborated with Bristol-Myers Squibb to develop a combination of Adcetris and Opdivo to treat hematologic malignancies. The drug Adcetris, originally developed by Seattle Genetics, is now being marketed in collaboration with Takeda in countries other than the US and Canada. Similarly, Vectibix, developed by Amgen, is now being marketed in collaboration with Takeda in Japan," says Barath. Browse Related Reports:
Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio's reports allows you to download any three reports per month for the price of one. Contact [email protected] with your requirements and a link to our subscription platform. About Technavio Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at [email protected]. View source version on businesswire.com: http://www.businesswire.com/news/home/20160502005557/en/ |
